Table 1.

Characteristics of patients enrolled and randomized in ELPh trial, and subdivided by those included in the analysis

Entire cohort (n = 500)Cohort Analyzed (n = 303)Participants not on LAM (n = 202)Participants on LAM (n = 101)P value
Age, median (range)59 (35, 89)59 (35, 84)58 (38, 83)61 (35, 84)0.002
BMI at diagnosis, median (range)29 (17.7, 55.9)29.3 (18.4, 55.9)28.6 (18.4, 53.4)30.5 (20.7, 55.9)0.02
Race, n (%)
 White441 (88)263 (87)176 (87)87 (86)0.81
 African American46 (9)34 (11)21 (10)13 (13)
 Asian12 (2)5 (2)4 (2)1 (1)
 Other1 (0)1 (0)1 (0)0 (0)
Treatment arm
 Exemestane248 (50)143 (47)94 (47)49 (49)0.81
 Letrozole252 (50)160 (53)108 (53)52 (51)
 Prior chemotherapy, n (%)228 (46)131 (43)98 (49)33 (33)0.01
 Prior tamoxifen use, n (%)184 (37)100 (33)70 (35)30 (30)0.44
 Years on tamoxifen, median (range)2.3 (0.1, 12.9)2.1 (0.1, 5.2)2.1 (0.1, 5.2)2.1 (0.2, 5)0.92

NOTE: P values for Fisher exact test or Wilcoxon rank sum tests for differences in patients on and not on lipid-altering medication (LAM).

Abbreviation: n, number.